201 related articles for article (PubMed ID: 18591715)
1. When to start antiretroviral therapy: a swinging pendulum?
Gallant JE
Top HIV Med; 2008; 16(2):82-8. PubMed ID: 18591715
[TBL] [Abstract][Full Text] [Related]
2. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
3. Early antiretroviral therapy: the role of cohorts.
Sabin CA
Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
[TBL] [Abstract][Full Text] [Related]
4. When and why to start antiretroviral therapy?
Gatell JM
J Antimicrob Chemother; 2010 Mar; 65(3):383-5. PubMed ID: 20071369
[TBL] [Abstract][Full Text] [Related]
5. Structured treatment interruptions--new findings.
Benson CA
Top HIV Med; 2006; 14(3):107-11. PubMed ID: 16946455
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
Sungkanuparph S; Anekthananon T; Hiransuthikul N; Bowonwatanuwong C; Supparatpinyo K; Mootsikapun P; Chetchotisakd P; Kiertiburanakul S; Tansuphaswadikul S; Buppanharun W; Manosuthi W; Techasathit W; Ratanasuwan W; Tantisiriwat W; Suwanagool S; Leechawengwongs M; Ruxrungtham K;
J Med Assoc Thai; 2008 Dec; 91(12):1925-35. PubMed ID: 19133532
[TBL] [Abstract][Full Text] [Related]
8. Strategic approaches to antiretroviral treatment.
Havlir DV
Top HIV Med; 2003; 11(4):145-9. PubMed ID: 12876333
[TBL] [Abstract][Full Text] [Related]
9. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.
De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Guèye NF; Guèye PM; Sow PS; Mboup S; Ndoye I; Ecochard R; Eric D;
Am J Trop Med Hyg; 2009 Jun; 80(6):1047-53. PubMed ID: 19478274
[TBL] [Abstract][Full Text] [Related]
10. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.
Deeks SG
Top HIV Med; 2009; 17(4):118-23. PubMed ID: 19890183
[TBL] [Abstract][Full Text] [Related]
11. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
12. When to start antiretroviral therapy?
Wilkin TJ; Gulick RM
Clin Infect Dis; 2008 Dec; 47(12):1580-6. PubMed ID: 18990069
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
14. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Mothi SN; Solomon S
J Trop Pediatr; 2009 Jun; 55(3):155-9. PubMed ID: 18829638
[TBL] [Abstract][Full Text] [Related]
16. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
17. Initiating therapy: when to start, what to use.
Hirsch MS
J Infect Dis; 2008 May; 197 Suppl 3():S252-60. PubMed ID: 18447611
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
19. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
20. Late presentation of HIV-infected individuals.
Battegay M; Fluckiger U; Hirschel B; Furrer H
Antivir Ther; 2007; 12(6):841-51. PubMed ID: 17926639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
